Overview

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nanjing Leads Biolabs Co.,Ltd